Abstract
GLP-1 is an incretin hormone that is naturally produced in the body that regulates blood glucose and appetite. The first GLP-1RA that was FDA approved, exenatide, in 2005, originated from the Gila monster and beaded lizard, via the discovery of the exendin-4 peptide. GLP-1RAs function by mimicking endogenous GLP-1 incretin hormone, leading to an increase in glucose-dependent insulin release from beta-cells of the pancreas, decrease in glucagon release, delayed gastric emptying, and satiety. Due to the benefits seen from initiating GLP-1RAs in the market, it sparked interest in numerous studies which proved that certain GLP-1RAs can provide cardiorenal protection. The indications for GLP-1RA use have also expanded beyond diabetes and weight management. The clinical evidence that supports the use of GLP-1RAs is typically applicable to the outpatient setting, with very limited information on its use within the inpatient setting.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Recommended Citation
Cordaro TA, Difaa SA, Basil AJ. Overview of GLP-1RA Medications. Transformative Medicine. 2026; 5(3):40-44. doi: https://doi.org/10.54299/tmed/cdwi6557.
Included in
Amino Acids, Peptides, and Proteins Commons, Endocrinology, Diabetes, and Metabolism Commons, Medical Pharmacology Commons, Pharmaceutical Preparations Commons